悪性Clioma患者におけるNeocarzinostatinの組織内動態 : ELISAによる定量法の確立

概要

論文の詳細を見る
Because of technical difficulties, the pharmacokinetics of neocarzinostatin (NCS) have not been thoroughly evaluated in patients with malignant glioma. The authors produced anti-NCS antibody by immunizing rabbits with NCS and established a means of quantifying tissue levels of NCS with enzyme-linked immunosorbent assay. In one patient given a bolus injection of 1 mg of NCS intraarterially, the concentration of drug in neoplastic tissue at 25 minutes (0.1136 μg/g) was higher than that in blood at 20 minutes and was retained for a longer period. Rapid entry of NCS into the tumor cavity was observed at 5 minutes. In two postoperative cases, NCS applied topically to the tumor site (50 and 100 μg) was retained at highlevels (0.2941 and 3.33 μg/ml) even after 48 hours, although no NCS was detected in blood after 60 minutes. NCS concentrations as low as 1 μg/ml demonstrated cytocidal effects, and a delay in tumor growth was observed even at an NCS level of 0.1 μg/ml, despite the fact that the half-life of NCS is extremely short (3 seconds in serum). Because its cytotoxic effect seems to be very rapid, it appears more important to obtain a high initial NCS concentration than to maintain a constant blood level.
日本脳神経外科学会の論文
1989-06-15